Document:

EX-10.31

 Exhibit 10.31 

AWARD AGREEMENT 

This Award Agreement (this “Agreement”), is made effective as of [•], between Teva Pharmaceutical Industries
Limited (the “Company”) and [•] (the “Participant”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2015 Long-Term Equity-Based
Incentive Plan (the “Plan”). 
 Pursuant to Sections 7 and 8 of the Plan, the Company hereby grants to the
Participant as of the Grant Date (as defined below) the number of Restricted Share Units (“RSUs”) and Performance Share Units (“PSUs”) (RSUs and PSUs are collectively and individually referred to herein
as “Awards”) set forth below, subject to the terms and conditions contained herein and in the appendices attached hereto, as well as the terms and conditions of the Plan and the Compensation Policy, as may be amended from time
to time at the Company’s sole discretion, which are incorporated herein in their entirety. All dollar amounts in this Agreement are in U.S. dollars. 
  

			
	Total Fair Value of the Award:	  	$[•]
		
	Fair Value of each RSU:	  	$[•]
		
	Fair Value of each PSU:	  	$[•]
		
	RSUs Granted:	  	[•], which represents approximately [•] of the Total Fair Value of the Award divided by the Fair Value of each RSU, rounded down to the nearest whole number.
		
	 Target Number of
 PSUs Granted:
	  	 [•], which represents approximately [•] of the Total Fair Value of the Award divided by the Fair Value of each
PSU, rounded down to the nearest whole number.
  
 The Target Number of PSUs Granted
represents the number of PSUs that would be earned, subject to vesting, if the Company were to achieve the target level of the PSU Performance Objectives and the target Relative TSR Modifier during the PSU Performance Period. The number of PSUs
earned, if any, is subject to an increase or decrease based on the Company’s actual achievement of the PSU Performance Objectives during the PSU Performance Period, as modified by the Relative TSR Modifier, and may range from
[•] to [•] of the Target Number of PSUs Granted.

		
	Grant Date:	  	[•]    

 W/3012824 

			
		
	Vesting of [•] of RSUs Granted:	  	[•] anniversary of the Grant Date, subject to the Participant’s continued employment through such date.
		
	Vesting of [•] of RSUs Granted:	  	[•] anniversary of the Grant Date, subject to the Participant’s continued employment through such date.
		
	Vesting of the Balance of RSUs Granted:	  	[•] anniversary of the Grant Date, subject to the Participant’s continued employment through such date.
		
	Settlement of Vested RSUs:	  	Upon vesting, RSUs shall be settled by delivering one Share for each RSU (or the cash value of one Share, if so determined by the Committee) that vested as soon as practicable, but in any event no later than thirty (30) days,
following the vesting date.
		
	PSU Performance Period:	  	[•]
		
	PSU Performance Objectives:	  	 •  [•] Performance Objective

 
 •  [•]
Performance Objective

		
	Relative TSR Modifier:	  	The “Relative TSR Modifier” will be determined based on the Company’s Relative TSR Percentile Rank for the PSU Performance Period, in accordance with the following table:

  

					
	 Achievement Level
	  	 Relative TSR

Percentile Rank
	  	Relative
TSR Modifier
	 Minimum
	  	Up to [•] Percentile	  	[•] %
	 Target
	  	[•] Percentile	  	[•] %
	 Maximum
	  	[•]Percentile or above	  	[•] %

  

			
		  	 Linear interpolation shall be used to determine the Relative TSR Modifier between Achievement Levels.

 
 For purposes hereof, the following terms have the following meanings:

 
 “Beginning Stock Price” with respect to any company means the average
of the closing prices of such company’s stock for each of the sixty (60) trading days ending on (and including) the day immediately prior to the first day of the PSU Performance
Period.

  
 - 2 - 

			
		  	 “Ending Stock Price” with respect to any company means the average of the closing prices of such company’s stock for
each of the sixty (60) trading days ending on (and including) the last day of the PSU Performance Period.
  

“Peer Group” means the following group of companies: [•] 

 
 “Relative TSR Percentile Rank” means the percentile rank of the TSR of
the Company relative to the TSR of the companies in the Peer Group, in each case, for the PSU Performance Period, equal to the product of (i) the quotient of (a) the numeric rank of Company’s TSR relative to the Peer Group, where the
lowest TSR in the Peer Group is ranked number 1, and (b) the total number of companies in the Peer Group plus 1, rounded to the nearest hundredth, and (ii) 100.
  

“TSR” as of a given date means the percentage change in the value of company’s stock from the Beginning Stock Price to the Ending Stock
Price calculated as the quotient of (i) (a) the applicable Ending Stock Price minus the applicable Beginning Stock Price, plus (b) dividends paid with respect to a record date occurring during the PSU Performance Period, divided by
(ii) the applicable Beginning Stock Price.

		
	Earned PSUs:	  	The number of PSUs earned, if any, subject to vesting (“Earned PSUs”), will be based on the achievement of the PSU Performance Objectives for the PSU Performance Period, as determined in accordance with the
following table and as adjusted by the Relative TSR Modifier. Performance will be measured for each PSU Performance Objective, and the arithmetic mean of the Applicable Earning Percentage of the [•] Performance Objective
and the Applicable Earning Percentage of the [•] Objective shall equal the Applicable Earning Percentage of the PSU Performance Objectives:

  

					
	 Achievement Level
	  	Percentage Achievement of
PSU Performance Objectives	 	Applicable Earning
Percentage
	 Below Threshold
	  	[•]	 	[•]
	 Threshold
	  	[•]	 	[•]
	 Target
	  	[•]	 	[•]
	 Maximum
	  	[•]	 	[•]
	 Above Maximum
	  	[•]	 	[•]

  
 - 3 - 

			
		  	 Linear interpolation shall be used to determine the Applicable Earning Percentage between Achievement Levels.

 
 The number of Earned PSUs shall equal the product of (i) the Target Number of PSUs
Granted, (ii) the Applicable Earning Percentage and (iii) the Relative TSR Modifier; provided, however, that the number of Earned PSUs shall not be greater than [•] % of the Target Number of PSUs
Granted.
  
 Any PSUs that do not become Earned PSUs based on performance during the
PSUs Performance Period shall not be eligible to vest pursuant to this Agreement and shall immediately be forfeited to the Company for no consideration upon expiration of the PSU Performance Period.

		
	Vesting Date of Earned PSUs (if any):	  	[•] anniversary of the Grant Date, subject to the Participant’s continued employment through such date.
		
	Settlement of Vested, Earned PSUs:	  	Upon vesting, Earned PSUs shall be settled by delivering one Share for each Earned PSU (or the cash value of one Share, if so determined by the Committee) that vested as soon as practicable, but in any event no later than thirty
(30) days, following the vesting date.

  
 - 4 - 

	1.	 Restricted Share Units. 

(A) Grant of RSUs. As set forth above, the Company hereby grants to the Participant, as of the Grant Date, the number of RSUs as set
forth in the table above. 
 (B) No Share Issuance at Grant. No Shares shall be issued or delivered to the Participant at the time the
RSUs are granted. 
  

	2.	 Performance Share Units. 

(A) Grant of PSUs. As set forth above, the Company hereby grants to the Participant, as of the Grant Date, the Target Number of PSUs
Granted as set forth in the table above. 
 (B) No Share Issuance at Grant. No Shares shall be issued or delivered to the Participant
at the time the PSUs are granted. 
 (C) Determination of the Earned PSUs. The Human Resources and Compensation Committee
(the “Committee”) and the Board shall have the sole authority to determine the level of achievement of the PSU Performance Objectives and the Relative TSR Modifier and to calculate the number of Earned PSUs, and shall do so as
soon as practicable following the completion of the PSU Performance Period and release of Financial Statements as set forth in the table above. For the avoidance of doubt, nothing herein shall derogate from the Committee’s and the Board’s
discretion to reduce variable compensation. 
 (D) Adjustment of PSU Performance Objectives. The Committee and, as applicable, the
Board shall have the discretion to adjust (increase or decrease) the PSU Performance Objectives and their relative weights as set forth in the table above if one or more of the following items of gain, loss, profit or expense, having a material
impact on the PSU Performance Objectives, is: (i) determined to be extraordinary, unusual or non-recurring in nature; (ii) related to changes in accounting principles under GAAP or tax laws;
(iii) related to currency fluctuations; (iv) related to productivity initiatives or new business initiatives; (v) related to discontinued operations that do not qualify as a segment of business under GAAP; or (vi) attributable to
the business operations or assets of any entity acquired or licensed by the Company during the fiscal year, to the extent the Committee or the Board, as applicable, determines that the adjustment is necessary or advisable to avoid the dilution or
enhancement of the intended incentives and benefits of the PSUs or if such adjustments were reflected in the Company’s public non-GAAP financial results. 

 

	3.	 Other Provisions. 

(A) Vesting. The Awards granted hereunder shall vest and settle as set forth in the table above. 

(B) Termination of Employment. In order to vest in the Awards, the Participant must be actively employed by the Company or its
Affiliates on the applicable vesting date, except as expressly provided in the Participant’s employment agreement including any amendment thereof and/or company policy applicable to Participant and/or the Plan. 

  
 - 5 - 

 (C) Withholding. The Company or the Employer, or a third party holding Awards on
behalf of the Participant, shall have the right to make all payments or distributions pursuant to this Agreement to the Participant net of any applicable taxes, fees or other required deductions, such as, but not limited to, income taxes, capital
gains taxes, social security premiums, and custody fees, trustee charges, fees for transfer of any Award or its underlying Share payable by the Participant or required to be paid or withheld as a result of the settlement of an RSU or a PSU, the
delivery of a Share or its transfer, and any other event occurring pursuant to the Plan or this Agreement, that necessitates the withholding of income, employment or capital gains taxes or any other required deductions or payments (hereinafter
referred to as “Taxes”). The Company or the Employer, may withhold from wages or other amounts payable to the Participant such Taxes as may be required by law or otherwise payable by the Participant, or to otherwise require the
Participant to pay such Taxes. 
 (D) Other Effective Documents; Other Agreements. 

 

	 	(i)	 The terms and provisions of the Compensation Policy and the Plan are incorporated herein by reference and made
a part hereof. In case of contradiction between the terms of this Agreement and/or its appendices and/or the Plan and/or the Compensation Policy, it is agreed that the terms of the Plan and the Compensation Policy shall prevail over the terms of
this Agreement and any appendix, and that the terms of any appendix shall prevail over the terms of this Agreement. The Participant agrees (x) that by not declining this Agreement within 30 days following Grant Date, he/she will become a party
to the agreements set forth in any appendix attached hereto, (y) to the terms of an Award administration framework agreement and its terms and conditions, as may be set forth in an appendix or as requested by the Company or the Employer in the
future, and shall also agree to such agreement in writing and (z) to the extent applicable, to adhere to the terms of the Company’s insider trading policy. In addition to any restrictions on resale and transfer noted in the Plan, Shares
acquired pursuant to the Plan may be subject to certain restrictions on resale and/or disclosure of such sale imposed by local securities laws. Accordingly, the Participant is encouraged to seek legal advice prior to any resale of such Shares.

  

	 	(ii)	 The Participant is advised to exercise caution regarding the Awards. If the Participant is in any doubt about
any provisions of the Plan or this Agreement, the Participant should obtain independent professional advice. Receiving Awards may have tax consequences under local tax laws. Neither the Company nor any of its Affiliates is responsible for, and has
not provided, any advice to the Participant regarding the Plan or the Awards, including but not limited to legal, investment or tax advice. 

  

	 	(iii)	 The Participant acknowledges and agrees that, if the Participant’s employment location changes or the
Participant’s employment transfers to a different Employer, whether the Participant will be able to continue participating in the Plan will depend on the Participant’s circumstances and will be determined by Teva in its discretion in
accordance with the Plan. 

  
 - 6 - 

 (E) Clawback/Recoupment Policy. By signing this Agreement, the Participant grants the
Employer a power of attorney to deduct from any payments due to the Participant by the Employer, any amounts owed by the Participant under Section 21(e) of the Plan, in accordance with applicable law. 

(F) Binding Effect. This Agreement shall be binding upon the heirs, executors, administrators, and successors of the parties hereto.

 (G) Governing Law. This Agreement (including, for the avoidance of doubt, any appendices attached hereto) shall be construed and
interpreted in accordance with the local laws of country where the Participant is or was last employed by the Employer without giving effect to the principles of the conflicts of laws thereof. 

(H) Entire Agreement; Modification. This Agreement (together with any appendices attached hereto) and the Plan constitute the entire
agreement between the parties relative to the subject matter hereof, and supersede all proposals, written or oral, and all other communications between the parties relating to the subject matter of this Agreement. This Agreement may be modified or
amended in accordance with Section 18 of the Plan. 
 (I) Counterparts; Electronic Signature. The award agreement shall be deemed
automatically accepted by the Participant and the Participant shall be subject to all its terms and conditions, unless the Participant clicks the “I decline” button at the end of the award agreement on Equate+ within 30 days following the
Grant Date. The Participant certifies that the Participant (A) has been furnished with all relevant information and materials with respect to the terms and conditions of the Award, (B) has read and understands such information and
materials, (C) is fully aware and knowledgeable of the terms and conditions of the Award, and (D) completely and voluntarily agrees to the terms and conditions of the Award, as set forth in the Plan and this Agreement. 

  
 - 7 -EX-10.32

 Exhibit 10.32 

Amendment to Employment Agreement 

This Amendment to the Employment Agreement (the “Amendment”) is entered into on this 5 day of February 2020 (the “Effective
Date”), and is made by and between TEVA PHARMACEUTICAL INDUSTRIES LTD., an Israeli corporation located at 5 Basel Street, Petach Tikwa, Israel, Company
No. 52-001395-4 (the “Company”, “Teva”), and Eli Kalif (“Executive”). 

WHEREAS, the Company and the Executive entered into an Employment Agreement dated November 6, 2019 (the “Agreement”); and 

WHEREAS, the Executive’s requested to limit the part of his Monthly Salary (as such term is defined in the Agreement) from which the
Company’s and the Executive’s contributions are made to the Study Fund in accordance with Sub Section 5.5 of the Agreement to 100,000 New Israeli Shekels (the “Maximum Cap”), and to receive the difference
between the contribution rates for the Study Fund set forth in Sub Section 5.5 of the Agreement and the contribution rates to the Maximum Cap, as a special supplement to the salary (hereinafter “Supplement in lieu of Study
Fund”); and 
 WHEREAS, the Company has accepted the Executive’s request subject to the terms detailed in this Amendment; 

NOW, THEREFORE, THE PARTIES HAVE AGREED AS FOLLOWS: 
  

	1.	 Capitalized terms used in this Amendment and not otherwise defined herein, shall bear the meaning
ascribed to them in the Agreement. 

  

	2.	 As of February 2020 Monthly’s Salary, the Company’s contribution to the Study Fund pursuant to
Sub Section 5.5 of the Agreement shall be made out of Monthly Salary only up to the Maximum Cap and the Company shall pay the Executive on a monthly basis the Supplement in lieu of Providence. 

 

	3.	 It is hereby acknowledged and agreed that the Supplement in lieu of Study Fund shall not be deemed part
of the Executive’s Salary for any purpose, including without derogating from the foregoing, for the purpose of payment of severance pay and any other entitlement calculated as a percentage of Executive’s Monthly Salary, and this Amendment
shall not impose on the Company any additional current or future cost or expense, directly or indirectly. 

  

	4.	 The Executive hereby explicitly waives any and all claim and/or demand and/or lawsuit of any kind with
respect to the scope of the Study Fund contributions. The Executive undertakes to indemnify the Company for any damage and/or cost and/or expense incurred by the Company as a result of any demand and/or lawsuit filed by him and/or on his behalf in
connection with the foregoing. 

  

	5.	 The Executive shall be entitled to cancel and/or modify the arrangement specified in this Amendment,
including the amount of the Maximum Cap, by providing the Company with a written request and the Company shall accept such request. For the sake of clarity, any such request made following the 15th
day of a month shall apply to Monthly Salaries of the following month in which such a request was made. 

	6.	 Unless explicitly set forth otherwise in this Amendment, the terms and conditions set forth in the
Agreement shall remain without change, binding and of full force and            effect. In event of conflict between the terms and conditions set forth in this Amendment and the terms and
conditions set forth in the Agreement, the terms set forth in this Amendment shall prevail. 

 IN WITNESS WHEREOF,
the parties have executed this Amendment in one or more counterparts as of the Effective Date. 
  

			
	TEVA PHARMACEUTICAL INDUSTRIES LTD.
		
		 	 /s/ Kåre Schultz

	By:	 	Kåre Schultz
	Title:	 	President and CEO
		
		 	 /s/ Mark Sabag

	By:	 	Mark Sabag
	Title:	 	Chief Human Resources Officer

  

	
	EXECUTIVE
	
	 /s/ Eli Kalif

	Name: Eli Kalif
	Dated: 06/02/2020

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}]]